Most common (≥5%) all-cause adverse events through Week 52 (safety population).
收藏数据链接：
官方服务：
资源简介：
*Intensification patients may have had an event during both the telbivudine only and intensification periods. Overall numbers with an indicated event may therefore be less than the row total.doi:10.1371/journal.pone.0054279.t003
创建时间：
2015-12-02
